AbCellera Biologics Inc. shares rise 15.80% premarket after reporting Q2 revenue beat estimates and beginning Phase 1 clinical trial for ABCL635.

Abcellera Biologics Inc. rose 15.80% in premarket trading, with the company reporting positive Q2 2025 earnings and beginning dosing in a Phase 1 clinical trial for ABCL635, a potential treatment for moderate-to-severe vasomotor symptoms associated with menopause. The company also announced that it has received authorization to initiate Phase 1 studies for both ABCL635 and ABCL575.